Expanding the customer base through drug discovery support services
First written in FY2020. 8 of 14 entries say "Advanced", first in FY2021-Q1. Latest entry: 2026-10-09.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「To address these risks, we are working to expand our customer base by developing new customers and capturing demand not only from pharmaceutical companies and emerging biopharmaceutical companies, but also from medical device and software (SaMD) developers, through the expansion of our global business and operations such as drug discovery support services in response to changing customer needs.」
Centered on the drug-discovery support business, the company is developing a specific strategy to expand its customer base beyond emerging biopharmaceutical companies to include medical-device and SaMD developers. It also continues sales activities targeting local companies and biotech firms in China and Taiwan. - 2026-06-10AdvancedPresentation materials on financial results
「Package offerings built around the drug discovery support business」
バイオ医薬品企業への対応について、創薬支援を入口にサービスをパッケージ展開する方法が具体化された。 - FY2026-H1RestatedAnnual report
「We will continue to focus on expanding transactions with existing customers and winning new projects from promising biotech companies in the promising U.S. market, and pursue sustainable growth.」
The company reaffirmed its policy of expanding transactions with existing customers and winning new projects from biotech companies in the U.S. market. - FY2025-H1AdvancedAnnual report
「We have been steadily winning new projects from U.S. biotech companies and others. We will continue to focus on deepening our presence in the U.S. CRO market and pursue sustainable growth.」
The company stated that it had steadily won new projects from U.S. biotech companies and others, indicating progress in expanding its customer base. - FY2024-Q3RestatedAnnual report
「Inquiries from U.S. biotech companies are currently strong. We will continue to focus on deepening our presence in the U.S. CRO market and pursue sustainable growth.」
The company indicated that inquiries from U.S. biotech companies were strong and continues to deepen its presence in the U.S. CRO market. - FY2024-Q2RestatedAnnual report
「Inquiries from U.S. biotech companies are currently strong. We will continue to focus on deepening our presence in the U.S. CRO market and pursue sustainable growth.」
The company indicated that inquiries from U.S. biotech companies were strong and continues to deepen its presence in the U.S. CRO market. - FY2024-Q1RestatedAnnual report
「The company is currently receiving inquiries regarding multiple projects from U.S. biotech companies and continues to negotiate with a view to winning these projects. We will continue to focus on deepening our presence in the U.S. CRO market and pursue sustainable growth.」
The company has received inquiries regarding multiple projects from U.S. biotech companies and continues negotiations to win the projects, while continuing to deepen its presence in the U.S. CRO market. - FY2023-Q1RestatedAnnual report
「We have received inquiries regarding multiple projects from U.S. biotech companies and continue to negotiate with a view to winning these projects. We will continue to focus on deepening our presence in the U.S. CRO market and pursue sustainable growth.」
The company has received inquiries regarding multiple projects from U.S. biotech companies and continues negotiations to win the projects, while continuing to deepen its presence in the U.S. CRO market. - FY2022-Q2AdvancedAnnual report
「Drug development in the U.S. market remains strong, with 2 biotech companies with which we have good relationships providing preliminary commitments for new projects and making inquiries about additional projects. We will continue to focus on winning new projects.」
The company stated that it had received preliminary commitments and inquiries regarding new projects from 2 biotech companies with which it has good relationships in the U.S. market. - FY2021-Q2AdvancedAnnual report
「Against this long-term trend, during the second half, when pharmaceutical companies formulate R&D budgets and development plans for the new fiscal year, inquiries for new projects are expected to increase, particularly in regions where the COVID-19 pandemic is relatively well controlled. As multiple projects frozen since the fourth quarter of the previous fiscal year are beginning to restart, the Group will work together to win these new projects.」
The company stated that inquiries for new projects were increasing and that multiple projects frozen since the fourth quarter of the previous fiscal year were beginning to restart. - FY2021-Q1AdvancedAnnual report
「However, in Japan, the company has received multiple new orders and preliminary commitments for products such as regenerative-medicine products from pharmaceutical companies and biotech ventures in Japan and overseas, while orders at its European subsidiary have also remained strong.」
The company stated that, as part of its customer-base expansion strategy, it had received multiple new orders and preliminary commitments for products such as regenerative-medicine products from pharmaceutical companies and biotech ventures in Japan and overseas. - FY2020First statedAnnual report
「To address these risks, we will work to expand our customer base by broadening our business, including drug-discovery support services, and capturing demand from biotech ventures in Japan and overseas.」
To address its dependence on specific pharmaceutical companies, the company stated for the first time its policy of capturing demand from biotech ventures in Japan and overseas by expanding its drug-discovery support services.